AbbVie (ABBV) Stock Price, News & Analysis

Company Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Key Stats

• Today's Range: $189.79 to $196.38
• 50-Day Range: $181.89 to $194.96
• 52-Week Range: $163.81 to $218.66
• Volume: 4.16 million shs
• Average Volume: 6.85 million shs
• Market Capitalization: $346.11 billion
• P/E Ratio: 83.39
• Dividend Yield: 3.35%
• Price Target: $212.81
• Consensus Rating: Moderate Buy

AbbVie Stock Analysis - MarketRank™

AbbVie scored higher than 92% of companies evaluated by MarketBeat, and ranked 119th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 16 buy ratings, 8 hold ratings, and no sell ratings.

Amount of Analyst Coverage

AbbVie has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 13.57%

Earnings Growth

Earnings for AbbVie are expected to grow by 13.57% in the coming year, from $12.31 to $13.98 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AbbVie is 83.21, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.20.

Price to Earnings Ratio vs. Sector

The P/E ratio of AbbVie is 83.21, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.48.

Price to Earnings Growth Ratio

AbbVie has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

AbbVie has a P/B Ratio of 103.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.89% of the float of AbbVie has been sold short.

Short Interest Ratio / Days to Cover

AbbVie has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AbbVie has recently decreased by 2.13%, indicating that investor sentiment is improving.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

AbbVie pays a meaningful dividend of 3.47%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

AbbVie has been increasing its dividend for 53 years.

Dividend Coverage

The dividend payout ratio of AbbVie is 279.15%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, AbbVie will have a dividend payout ratio of 46.92% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.34

Percentage of Shares Shorted

0.89% of the float of AbbVie has been sold short.

Short Interest Ratio / Days to Cover

AbbVie has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AbbVie has recently decreased by 2.13%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.06

News Sentiment

AbbVie has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 134 news articles for AbbVie this week, compared to 66 articles on an average week.

Search Interest

146 people have searched for ABBV on MarketBeat in the last 30 days. This is an increase of 62% compared to the previous 30 days.

MarketBeat Follows

52 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 148% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AbbVie insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.25% of the stock of AbbVie is held by insiders.

Percentage Held by Institutions

70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABBV Stock Analysis - Frequently Asked Questions

How have ABBV shares performed this year?

AbbVie's stock was trading at $177.70 at the start of the year. Since then, ABBV stock has increased by 10.2% and is now trading at $195.8960.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings data on Thursday, July, 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.24 by $0.27. The company's quarterly revenue was up 6.6% on a year-over-year basis.
Read the conference call transcript.

Does AbbVie have any subsidiaries?

AbbVie subsidiaries include these companies: Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and more.

Who are AbbVie's major shareholders?

Top institutional shareholders of AbbVie include Envestnet Asset Management Inc. (0.30%), Nordea Investment Management AB (0.25%), Assenagon Asset Management S.A. (0.25%) and Sumitomo Mitsui Trust Group Inc. (0.24%). Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Robert A Michael, Nicholas Donoghoe, Jeffrey Ryan Stewart, Timothy J Richmond, Roxanne S Austin, Carrie C Strom, Elaine K Sorg, Scott T Reents, Perry C Siatis and Kevin K Buckbee.
View institutional ownership trends.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Chevron (CVX), Vanguard Short-Term Inflation-Protected Securities ETF (VTIP), Salesforce (CRM) and Intact Financial (IFC).

Company Calendar

• Record date for 5/15 Dividend: 4/15/2025
• Ex-Dividend for 5/15 Dividend: 4/15/2025
• Dividend Payable: 5/15/2025
• Record date for 8/15 Dividend: 7/15/2025
• Ex-Dividend for 8/15 Dividend: 7/15/2025
• Last Earnings: 7/31/2025
• Today: 8/01/2025
• Dividend Payable: 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:ABBV
• CIK: 1551152
• Web: www.abbvie.com
• Phone: (847) 932-7900
• Fax: 302-655-5049
• Employees: 55,000
• Year Founded: 2013

Price Target and Rating

• Average Price Target for AbbVie: $212.81
• High Price Target: $255.00
• Low Price Target: $180.00
• Potential Upside/Downside: +10.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.81
• Research Coverage: 27 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.35
• Trailing P/E Ratio: 82.43
• Forward P/E Ratio: 15.71
• P/E Growth: 1.25
• Net Income: $4.28 billion
• Net Margins: 7.31%
• Pretax Margin: 6.31%
• Return on Equity: 412.03%
• Return on Assets: 13.11%

Debt

• Debt-to-Equity Ratio: 44.14
• Current Ratio: 0.76
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: $56.33 billion
• Price / Sales: 6.06
• Cash Flow: $15.25 per share
• Price / Cash Flow: 12.68
• Book Value: $1.90 per share
• Price / Book: 101.77

Miscellaneous

• Outstanding Shares: 1,766,400,000
• Free Float: 1,761,987,000
• Market Cap: $341.54 billion
• Optionable: Optionable
• Beta: 0.48